Edition:
United Kingdom

Johnson & Johnson Reports Q2 Adjusted EPS Of $2.58


Tuesday, 16 Jul 2019 

July 16 (Reuters) - Johnson & Johnson ::REPORTS 2019 SECOND-QUARTER RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $2.58.Q2 EARNINGS PER SHARE $2.08.Q2 EARNINGS PER SHARE ESTIMATE $2.46 -- REFINITIV IBES DATA.Q2 REVENUE $20.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.29 BILLION.OPERATIONAL SALES GUIDANCE INCREASED DUE TO STRENGTH OF BUSINESS; EPS GUIDANCE RANGE MAINTAINED.QTRLY OPERATIONAL GROWTH OF 1.6% AND ADJUSTED OPERATIONAL GROWTH OF 3.7%."PIPELINES CONTINUE TO PROGRESS WITH LAUNCH OF NEW PRODUCTS AND SEVERAL REGULATORY SUBMISSIONS AND APPROVALS".QTRLY PHARMACEUTICAL WORLDWIDE OPERATIONAL SALES, EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES GREW 4.4%.QTRLY GAAP NET LITIGATION EXPENSE $409 MILLION VERSUS $703 MILLION.SEES FY 2019 ADJUSTED OPERATIONAL SALES CHANGE VERSUS. PRIOR YEAR 3.2% - 3.7%.SEES FY ADJUSTED EPS $8.53 TO $8.63.QTRLY WORLDWIDE REMICADE SALES $1,107 MILLION VERSUS $1,320 MILLION.SEES FY 2019 OPERATIONAL SALES $82.4 BILLION TO $83.2 BILLION.QTRLY WORLDWIDE IMBRUVICA SALES $831 MILLION VERSUS $620 MILLION.SEES FY 2019 ESTIMATED REPORTED SALES $80.8 BILLION TO $81.6 BILLION.FY2019 EARNINGS PER SHARE VIEW $8.60, REVENUE VIEW $81.22 BILLION -- REFINITIV IBES DATA.QTRLY WORLDWIDE ZYTIGA SALES $698 MILLION VERSUS $909 MILLION.QTRLY WORLDWIDE STELARA SALES $1,558 MILLION VERSUS $1,341 MILLION. 

Company Quote

15.59
0.36 +2.36%
16 Aug 2019